fertility-health
Thyroid Disorders and Fertility: How Hypothyroidism and Hyperthyroidism Affect Conception
Dr. Carolina Gallardo
Polycystic Ovary Syndrome (PCOS)
PCOS is the most common hormonal disorder in women of reproductive age — and one of the most treatable causes of ovulatory infertility.
Affects 1 in 10 women of reproductive age (6–12% globally)
Leading cause of anovulatory infertility in the USDiagnosed by Rotterdam criteria: 2 of 3 findings (irregular cycles, hyperandrogenism, polycystic ovaries on ultrasound)Associated with insulin resistance in up to 70% of cases (Azziz et al., JCEM 2004)Letrozole is now the evidence-based first-line ovulation induction agent (ASRM 2023 Practice Bulletin)IVF success rates for PCOS patients under 35 are among the highest of any diagnostic group
Find Clinics That Specialize in PCOSHow PCOS Affects Fertility
PCOS disrupts the hormonal signals that govern the menstrual cycle, leading to chronic anovulation — the failure to release an egg each month. Elevated luteinizing hormone (LH) and insulin levels suppress follicle-stimulating hormone (FSH) signaling, causing follicles to stall in mid-development. The result is the characteristic "string of pearls" appearance on ultrasound: multiple small, immature follicles that never reach ovulatory maturity. Without ovulation, conception is not possible without medical intervention. The ASRM estimates that PCOS accounts for roughly 70% of all anovulatory infertility cases (ASRM Practice Bulletin, Obstet Gynecol 2020).
Beyond ovulation, PCOS affects the broader hormonal environment of early pregnancy. Elevated androgens (testosterone, DHEAS) and chronic low-grade inflammation may impair endometrial receptivity, though the evidence here is less definitive. Insulin resistance — present in the majority of PCOS patients regardless of weight — raises early miscarriage risk through multiple pathways, including elevated LH surges, abnormal glucose metabolism, and altered endometrial gene expression. For women with PCOS who do conceive, rates of gestational diabetes, pregnancy-induced hypertension, and preterm birth are modestly elevated, underscoring the importance of pre-conception optimization and close obstetric monitoring.
The good news is that PCOS is among the most treatment-responsive fertility diagnoses. Because the underlying problem is hormonal rather than anatomical, interventions that restore ovulation — whether through lifestyle changes, medications, or assisted reproduction — typically achieve excellent outcomes. Women with PCOS who undergo IVF produce more eggs than average, which translates to more embryos, more opportunities for preimplantation genetic testing, and better cumulative live birth rates over multiple frozen embryo transfer cycles.
Treatment Options
Treatment is individualized based on age, severity, duration of infertility, and partner factors. Work with your reproductive endocrinologist to determine the right sequence for your specific situation.
First-line treatment
Lifestyle Modification
A 5–10% reduction in body weight restores spontaneous ovulation in approximately 50–60% of overweight women with PCOS (Kiddy et al., Clin Endocrinol 1992; Moran et al., Hum Reprod Update 2011). A Mediterranean-style diet low in refined carbohydrates, combined with 150 minutes of moderate aerobic exercise per week, reduces insulin resistance and androgen levels. Lifestyle change should be offered before or alongside pharmacological treatment.
First-line treatment
Letrozole (Femara)
Letrozole, an aromatase inhibitor given orally on cycle days 2–6 (2.5–7.5 mg/day), is the recommended first-line ovulation induction agent per ASRM 2023 guidelines. The landmark NICHD PPCOS II trial (Legro et al., NEJM 2014) showed letrozole achieved higher live birth rates (27.5%) than clomiphene (19.1%) with fewer multiple gestations. Monitoring with transvaginal ultrasound is recommended to confirm ovulation.
Typical success rate
27–40% live birth rate per ovulatory cycle in PCOS patients
Clomiphene Citrate
Clomiphene (50–150 mg on cycle days 2–6) was the historical first-line agent for anovulatory PCOS for decades. It achieves ovulation in 70–85% of patients but lower conception rates than letrozole, and carries a higher twin rate (~8%). Clomiphene may be considered when letrozole is unavailable, though most guidelines now prefer letrozole. Maximum treatment duration is typically 6 ovulatory cycles (ASRM 2023).
Typical success rate
22–30% live birth rate per ovulatory cycle
Metformin
Metformin (1,500–2,000 mg/day) improves insulin sensitivity and can restore menstrual regularity, but is less effective than letrozole as monotherapy for ovulation induction (Legro et al., NEJM 2007). It is most useful as an adjunct to reduce ovarian hyperstimulation syndrome (OHSS) risk during IVF and to lower early miscarriage rates. ASRM recommends its use in PCOS patients undergoing IVF who are at high OHSS risk.
Ovarian Drilling (Laparoscopic)
Laparoscopic ovarian drilling (LOD) uses electrosurgical or laser energy to create small punctures in the ovarian cortex, reducing androgen-producing stromal tissue and normalizing LH/FSH ratios. A Cochrane review (van Wely et al., 2011) found comparable cumulative live birth rates to gonadotropin therapy, with a significantly lower multiple pregnancy rate. LOD is reserved for clomiphene-resistant patients or those undergoing laparoscopy for another indication.
Typical success rate
54–70% ovulation rate; cumulative pregnancy rates similar to gonadotropins
Gonadotropins (Injectable FSH)
Injectable FSH (typically 37.5–75 IU/day, low-dose step-up protocol) directly stimulates follicular development. Highly effective for ovulation induction but carries significant multiple pregnancy risk (20–30% twin rate) and OHSS risk if not carefully monitored. Generally reserved for patients who fail oral agents. Requires intensive ultrasound and hormone monitoring and is typically managed by a reproductive endocrinologist (ASRM Practice Bulletin 2020).
Typical success rate
20–25% pregnancy rate per cycle with careful monitoring
Intrauterine Insemination (IUI)
IUI with ovulation induction (letrozole or gonadotropins) places washed sperm directly into the uterine cavity at the time of ovulation, reducing the distance sperm must travel. IUI is typically offered for 3–6 cycles before escalation to IVF. It requires at least one patent fallopian tube (confirmed by hysterosalpingogram) and adequate male factor parameters. Combined with letrozole, IUI is a cost-effective step before IVF in women under 38.
Typical success rate
12–18% per cycle with letrozole; cumulative 40–50% over 3–6 cycles
IVF (In Vitro Fertilization)
IVF is highly effective for PCOS and is recommended when oral agents fail, tubes are blocked, or male factor is present. Women with PCOS produce more eggs than average during stimulation, increasing the embryo cohort and cumulative live birth potential. The GnRH antagonist protocol with a GnRH agonist trigger (instead of hCG) dramatically reduces OHSS risk and is standard practice for PCOS patients. Freeze-all strategies with deferred frozen embryo transfer (FET) further reduce OHSS risk and optimize endometrial receptivity (Chen et al., NEJM 2016).
Typical success rate
40–55% live birth rate per egg retrieval for women under 35 with PCOS
What Patients with PCOS Can Expect
PCOS patients generally have favorable fertility treatment outcomes because the underlying problem is hormonal rather than anatomical, and ovarian reserve is typically preserved or even elevated. Live birth rates are among the highest of any infertility diagnosis when age is controlled. However, OHSS risk requires careful management, and freeze-all IVF cycles are increasingly standard practice.
| Treatment | Typical Success Range |
|---|---|
| Lifestyle modification alone (BMI reduction) | 50–60% ovulation restoration |
| Letrozole ovulation induction | 27–40% live birth per ovulatory cycle |
| Clomiphene citrate | 22–30% live birth per ovulatory cycle |
| Gonadotropins + timed intercourse | 20–25% per cycle |
| Letrozole + IUI | 12–18% per cycle; ~45% cumulative over 3–6 cycles |
| IVF (fresh transfer) | 35–45% live birth per transfer (age < 35) |
| IVF (freeze-all + FET) | 40–55% live birth per transfer (age < 35) |
Individual outcomes vary significantly based on age, ovarian reserve, partner factors, and clinic expertise. These figures are based on published research (ASRM, SART, Cochrane Reviews) and national averages — they are not guarantees. Ask your clinic for their own reported outcomes for your specific diagnosis and age group.
Questions to Ask Your Reproductive Endocrinologist
Bring this list to your first consultation to make the most of your appointment.
- 1
Should I try letrozole or clomiphene first, and how will we monitor my response?
- 2
Given my PCOS, what is my OHSS risk with IVF and how will you mitigate it?
- 3
Do you recommend a freeze-all strategy for my IVF cycle, and why?
- 4
Should I be tested for insulin resistance, and would metformin improve my outcomes?
- 5
How many IUI cycles do you recommend before moving to IVF?
- 6
What is my antral follicle count (AFC) and AMH, and what do they mean for my treatment plan?
- 7
What lifestyle changes would have the most impact on my ovulation before we start medications?
- 8
Do you screen for endometrial hyperplasia given my irregular cycles?
When to See a Specialist
Women with PCOS should see a reproductive endocrinologist (RE) after 12 months of trying to conceive (6 months if over 35), or sooner if cycles are significantly irregular (fewer than 8 per year) or absent. If you have already been diagnosed with PCOS and are planning pregnancy, an RE consultation before you start trying is worthwhile to establish a treatment plan.
Ready to Find a Clinic That Specializes in PCOS?
Look for clinics with reproductive endocrinologists (REs) who have documented experience treating PCOS. Ask about their specific outcomes for your diagnosis and age group during your first consultation — outcomes vary significantly by clinic.
Select your state to browse fertility clinics near you:
Related Articles
IVF
Beta hCG After IVF: What Your First Result Means
Your first beta hCG result after IVF is one of the most nerve-wracking numbers in the entire process. This guide explains what it means, what doubling times to expect, how to interpret a borderline result, and what comes next.
Dr. Hannah Ní Bhriain Russell
IVF
OHSS After IVF: Symptoms, Classification, Prevention & Treatment
Ovarian hyperstimulation syndrome is the most serious complication of IVF stimulation. This guide covers who is at risk, how severity is graded, evidence-based prevention strategies, and what to do if symptoms develop.
Dr. Hannah Ní Bhriain Russell
IVF
ICI vs IUI vs IVF: Which Treatment Should You Start With?
The right starting point for fertility treatment is never the same for everyone — it depends entirely on your diagnosis. This guide gives you a clear, evidence-based framework for deciding between ICI, IUI, and IVF.
Prof. Jane Harries
Related Conditions
Endometriosis
Affects ~10% of reproductive-age women; up to 50% of infertile women
Learn moreMale Factor Infertility
Contributes to 40–50% of all infertility cases; sole cause in ~20% of couples
Learn moreUnexplained Infertility
Diagnosed in 15–30% of infertile couples after standard evaluation
Learn more